Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:55 AM
Ignite Modification Date: 2025-12-25 @ 2:55 AM
NCT ID: NCT05936333
Eligibility Criteria: Family Inclusion Criteria: * Mother and father ≥ 18 years old * For mothers in the CHI group : * History of a normal pregnancy (full term, alive child) or IUGR/MFIU or miscarriage(s) or abortion followed by at least 1 obstetrical complication such as IUGR, MFIU, miscarriage * Diagnosis of chronic histiocytic intervillitis made by placental anatomopathological examination with CD68+ marking * For the mothers of the antiphospholipid syndrom group * History of miscarriage(s) * Having an anti-phospholipid syndrome * For mothers in the normal pregnancy group: * Third consecutive pregnancy of normal course, at term (≥ 36 weeks of amenorrhea) with eutrophic child For the mother and father: o Consent to participate in the study and for the participation in the study of at least one child and/or the use of existing samples (placenta / fetal DNA) from at least one previous pregnancy with CHI for the CHI group or at least one previous miscarriage for the APS group For the father: o Father of the last pregnancy and of the child(ren) participating in the study Exlusion criteria : * For mothers in the normal pregnancy group: o Suspected or confirmed intra-amniotic infection * For all the mothers: * History of blood transfusion * History of allogeneic organ transplantation * For the mother and the father: * Person under legal protection (guardianship, curatorship)
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT05936333
Study Brief:
Protocol Section: NCT05936333